Arcturus Therapeutics
ARCT
162 hedge funds and large institutions have $776M invested in Arcturus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 51 increasing their positions, 40 reducing their positions, and 26 closing their positions.
104% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 26
28% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 40
24% more call options, than puts
Call options by funds: $31.2M | Put options by funds: $25.2M
20% more funds holding
Funds holding: 135 → 162 (+27)
5.43% less ownership
Funds ownership: 76.92% → 71.49% (-5.4%)
10% less capital invested
Capital invested by funds: $865M → $776M (-$89.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
+$14.2M |
| 3 |
Two Sigma Investments
New York
|
+$13.7M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$10.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$73.9M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$37.4M |
| 3 |
Goldman Sachs
New York
|
-$15.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$14.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.54M |
ARCT Hedge Fund Activity: Q1 2021 in Review
162 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2021, worth a combined $776M — down 10% from $865M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ARCT positions and 26 closed out — a net gain of 27 holders — while 51 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $23M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.9M.
- 162 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2021, up from 135 in Q4 2020.
- Funds reported $776M of Arcturus Therapeutics stock for Q1 2021, down 10% quarter-over-quarter.
- 53 funds opened new Arcturus Therapeutics positions in Q1 2021 and 26 closed out, a net change of +27 holders.
- The largest Arcturus Therapeutics buyer in Q1 2021 was State Street, an estimated $23M added.
- The largest Arcturus Therapeutics seller in Q1 2021 was T. Rowe Price Associates, an estimated $73.9M sold.
Based on aggregated 13F filings for Q1 2021.